How to Buy jbchepharm Shares on Fincept?
You can buy J. B. Chemicals & Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: J. B. Chemicals & Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Jbchepharm, including updates on board meetings and corporate actions.
J. B. Chemicals & Pharmaceuticals Limited - https://www.jbpharma.com
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
J. B. Chemicals & Pharmaceuticals Limited Share Price Today
1,707.15
OPEN
1,766.75
HIGH
1,707.00
LOW
1,746.00
CLOSE
26 K
VOLUME
28,548 Cr
Market Cap
222293
Average Volume
Healthcare
Sector
NSI
Exchange
J. B. Chemicals & Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: JBCHEPHARM Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
INE572A01028 |
Dividend - Rs 6.75 Per Share |
14 Aug 2024 |
1 |
N/A |
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
INE572A01028 |
Interim Dividend - Rs 5.50 Per Share |
16 Feb 2024 |
1 |
N/A |
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
INE572A01028 |
Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share |
18 Sep 2023 |
1 |
N/A |
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
INE572A01028 |
Dividend - Rs 9.25 Per Share |
17 Aug 2023 |
1 |
N/A |
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
INE572A01028 |
Interim Dividend - Rs 8.50 Per Share |
17 Feb 2023 |
1 |
N/A |
NSE: JBCHEPHARM Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
JBCHEPHARM |
27 Dec 2024, 14:37:33 |
Trading Window-XBRL |
Pharmaceuticals |
JBCHEPHARM |
27 Dec 2024, 14:30:13 |
Trading Window |
Pharmaceuticals |
JBCHEPHARM |
18 Dec 2024, 14:37:44 |
Alteration Of Capital and Fund Raising-XBRL |
Pharmaceuticals |
JBCHEPHARM |
18 Dec 2024, 14:28:09 |
ESOP/ESOS/ESPS |
Pharmaceuticals |
JBCHEPHARM |
07 Dec 2024, 10:09:50 |
Alteration Of Capital and Fund Raising-XBRL |
Pharmaceuticals |
NSE: JBCHEPHARM Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
18 Oct 2024, 16:28:00 |
18 Oct 2024, 16:28:00 |
|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
19 Jul 2024, 16:25:00 |
19 Jul 2024, 16:25:00 |
|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
19 Apr 2024, 15:22:00 |
19 Apr 2024, 15:45:00 |
|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
19 Jan 2024, 16:45:00 |
19 Jan 2024, 17:15:00 |
|
JB Chemicals & Pharmaceuticals Limited |
JBCHEPHARM |
18 Oct 2023, 17:45:00 |
18 Oct 2023, 18:15:00 |
NSE: JBCHEPHARM Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Independent Director,Chairperson & Non-Executive Director |
01 Oct 1946 |
05 Jul 2024 |
00024262 |
Arun Duggal |
Active |
Independent Director |
29 Mar 1954 |
31 Aug 2020 |
03340616 |
Sumit Bose |
Active |
Independent Director |
15 Apr 1965 |
31 Aug 2020 |
00296388 |
Padmini Khare Kaicker |
Active |
Non-Executive Director |
23 Nov 1975 |
10 Feb 2021 |
03467781 |
Gaurav Trehan |
Active |
Non-Executive Director |
04 Jul 1976 |
31 Aug 2020 |
08342577 |
Prashant Kumar |
Active |
NSE: JBCHEPHARM Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
JB CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . |
JBCHEPHARM |
N/A |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
25 Oct 2024, 17:07:51 |
Financial Results |
JBCHEPHARM |
N/A |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
26 Jul 2024, 17:10:10 |
Financial Results/Dividend |
JBCHEPHARM |
N/A |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
10 May 2024, 17:46:09 |
JB CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Dividend. |
JBCHEPHARM |
N/A |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
30 Jan 2024, 18:33:02 |
JB CHEMICALS & PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2023 . |
JBCHEPHARM |
N/A |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
30 Oct 2023, 18:37:02 |
NSE: JBCHEPHARM Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
JBCHEPHARM |
- |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
25 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
JBCHEPHARM |
- |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
26 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
JBCHEPHARM |
- |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
10 May 2024, 00:00:00 |
To consider and approve the audited financial results for the year and quarter ended March 31, 2024 and consideration and recommendation of dividend on equity shares of the Company, if any, subject to approval of shareholders |
Financial Results/Dividend |
JBCHEPHARM |
- |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
30 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 and dividend |
Financial Results |
JBCHEPHARM |
- |
INE572A01028 |
JB Chemicals & Pharmaceuticals Limited |
30 Oct 2023, 00:00:00 |
To consider and approve the unaudited financial results for the quarter and half year ended on September 30, 2023 |
NSE: JBCHEPHARM Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Held To Maturity Securities | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Trading Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Current Deferred Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 155,314,408.00 | 155,314,408.00 | 0.00 | 1,002,100,000.00 | 17,964,200,000.00 | 32,938,700,000.00 | 12,913,800,000.00 | 17,964,200,000.00 | 185,700,000.00 | 32,122,300,000.00 | 32,122,300,000.00 | 32,122,300,000.00 | 0.00 | 32,122,300,000.00 | 31,967,000,000.00 | 0.00 | 0.00 | 155,300,000.00 | 155,300,000.00 | 8,171,800,000.00 | 1,952,600,000.00 | 16,900,000.00 | 0.00 | 0.00 | 1,641,200,000.00 | 74,600,000.00 | 74,600,000.00 | 0.00 | 219,900,000.00 | 6,219,200,000.00 | 197,400,000.00 | 0.00 | 927,500,000.00 | 111,100,000.00 | 816,400,000.00 | 0.00 | 621,600,000.00 | 3,663,000,000.00 | 0.00 | 0.00 | 238,100,000.00 | 3,424,900,000.00 | 40,294,100,000.00 | 21,161,100,000.00 | 14,900,000.00 | 0.00 | 0.00 | 52,200,000.00 | 361,700,000.00 | 0.00 | 361,700,000.00 | 0.00 | 0.00 | 14,158,100,000.00 | 13,583,500,000.00 | 574,600,000.00 | 6,416,700,000.00 | 0.00 | 6,416,700,000.00 | 419,600,000.00 | 5,997,100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19,133,000,000.00 | 1,228,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,436,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6,100,000.00 | 0.00 | 8,165,300,000.00 | 0.00 | 0.00 | 4,296,500,000.00 | 3,397,600,000.00 | 898,900,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 155,194,800.00 | 155,194,800.00 | 2,689,259,000.00 | 3,776,559,000.00 | 14,774,155,000.00 | 32,804,703,000.00 | 9,851,192,000.00 | 14,774,155,000.00 | 205,149,000.00 | 29,233,293,000.00 | 29,469,680,000.00 | 29,233,293,000.00 | 0.00 | 29,233,293,000.00 | 1,398,387,000.00 | 25,170,103,000.00 | 1,148,998,000.00 | 155,195,000.00 | 155,195,000.00 | 10,707,978,000.00 | 2,025,717,000.00 | 17,000,000.00 | 183,883,000.00 | 16,988,000.00 | 1,492,076,000.00 | 332,770,000.00 | 96,383,000.00 | 236,387,000.00 | 183,900,000.00 | 8,682,261,000.00 | 242,000,000.00 | 0.00 | 3,443,789,000.00 | 108,766,000.00 | 3,335,023,000.00 | 0.00 | 490,592,000.00 | 4,563,267,000.00 | 866,060,000.00 | 16,484,000.00 | 117,620,000.00 | 3,563,103,000.00 | 39,941,271,000.00 | 21,407,818,000.00 | 3,000.00 | 63,978,000.00 | 0.00 | 58,777,000.00 | 285,134,000.00 | 0.00 | 48,052,000.00 | 237,082,000.00 | 0.00 | 14,459,138,000.00 | 13,884,546,000.00 | 574,592,000.00 | 6,385,011,000.00 | -7,003,774,000.00 | 13,388,785,000.00 | 669,409,000.00 | 886,178,000.00 | 7,932,934,000.00 | 3,499,500,000.00 | 400,764,000.00 | 0.00 | 18,533,453,000.00 | 1,903,100,000.00 | 7,631,000.00 | 0.00 | 16,484,000.00 | 1,851,650,000.00 | 5,025,128,000.00 | 412,925,000.00 | 2,407,217,000.00 | 239,545,000.00 | 1,965,441,000.00 | 167,019,000.00 | 0.00 | 6,869,188,000.00 | -158,526,000.00 | 7,027,714,000.00 | 4,596,353,000.00 | 3,714,202,000.00 | 882,151,000.00 | 235,016,000.00 | 647,135,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 155,194,800.00 | 155,194,800.00 | 2,689,259,000.00 | 3,776,559,000.00 | 14,774,155,000.00 | 32,804,703,000.00 | 9,851,192,000.00 | 14,774,155,000.00 | 205,149,000.00 | 29,233,293,000.00 | 29,469,680,000.00 | 29,233,293,000.00 | 0.00 | 29,233,293,000.00 | 1,398,387,000.00 | 25,170,103,000.00 | 1,148,998,000.00 | 155,195,000.00 | 155,195,000.00 | 10,707,978,000.00 | 2,025,717,000.00 | 17,000,000.00 | 183,883,000.00 | 16,988,000.00 | 1,492,076,000.00 | 332,770,000.00 | 96,383,000.00 | 236,387,000.00 | 183,900,000.00 | 8,682,261,000.00 | 242,000,000.00 | 0.00 | 3,443,789,000.00 | 108,766,000.00 | 3,335,023,000.00 | 0.00 | 490,592,000.00 | 4,563,267,000.00 | 866,060,000.00 | 16,484,000.00 | 117,620,000.00 | 3,563,103,000.00 | 39,941,271,000.00 | 21,407,818,000.00 | 3,000.00 | 63,978,000.00 | 0.00 | 58,777,000.00 | 285,134,000.00 | 0.00 | 48,052,000.00 | 237,082,000.00 | 0.00 | 14,459,138,000.00 | 13,884,546,000.00 | 574,592,000.00 | 6,385,011,000.00 | -7,003,774,000.00 | 13,388,785,000.00 | 669,409,000.00 | 886,178,000.00 | 7,932,934,000.00 | 3,499,500,000.00 | 400,764,000.00 | 0.00 | 18,533,453,000.00 | 1,903,100,000.00 | 7,631,000.00 | 0.00 | 16,484,000.00 | 1,851,650,000.00 | 5,025,128,000.00 | 412,925,000.00 | 2,407,217,000.00 | 239,545,000.00 | 1,965,441,000.00 | 167,019,000.00 | 0.00 | 6,869,188,000.00 | -158,526,000.00 | 7,027,714,000.00 | 4,596,353,000.00 | 3,714,202,000.00 | 882,151,000.00 | 235,016,000.00 | 647,135,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 154,955,510.00 | 154,955,510.00 | 3,354,800,000.00 | 4,503,700,000.00 | 13,640,700,000.00 | 31,438,100,000.00 | 11,152,300,000.00 | 13,640,700,000.00 | 232,700,000.00 | 27,167,100,000.00 | 29,957,900,000.00 | 27,167,100,000.00 | 0.00 | 27,167,100,000.00 | 27,012,100,000.00 | 0.00 | 0.00 | 155,000,000.00 | 155,000,000.00 | 10,824,900,000.00 | 4,397,700,000.00 | 22,700,000.00 | 0.00 | 0.00 | 1,274,000,000.00 | 2,923,000,000.00 | 132,200,000.00 | 2,790,800,000.00 | 178,000,000.00 | 6,427,200,000.00 | 183,300,000.00 | 0.00 | 1,580,700,000.00 | 100,500,000.00 | 1,480,200,000.00 | 0.00 | 564,400,000.00 | 3,419,800,000.00 | 0.00 | 0.00 | 195,700,000.00 | 3,224,100,000.00 | 37,992,000,000.00 | 20,412,500,000.00 | 9,900,000.00 | 0.00 | 0.00 | 54,000,000.00 | 246,000,000.00 | 0.00 | 246,000,000.00 | 0.00 | 0.00 | 13,526,400,000.00 | 12,951,800,000.00 | 574,600,000.00 | 6,370,200,000.00 | 0.00 | 6,370,200,000.00 | 724,400,000.00 | 5,645,800,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17,579,500,000.00 | 1,714,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,245,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12,600,000.00 | 0.00 | 7,147,000,000.00 | 0.00 | 0.00 | 4,460,600,000.00 | 3,544,400,000.00 | 916,200,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 154,755,168.00 | 154,755,168.00 | 4,713,039,000.00 | 5,724,462,000.00 | 11,006,120,000.00 | 30,285,905,000.00 | 9,735,837,000.00 | 11,006,120,000.00 | 242,079,000.00 | 24,803,522,000.00 | 28,635,725,000.00 | 24,803,522,000.00 | 0.00 | 24,803,522,000.00 | 1,216,210,000.00 | 21,250,814,000.00 | 712,098,000.00 | 154,755,000.00 | 154,755,000.00 | 10,735,184,000.00 | 5,190,691,000.00 | 25,000,000.00 | 152,114,000.00 | 24,927,000.00 | 1,028,237,000.00 | 3,985,413,000.00 | 153,210,000.00 | 3,832,203,000.00 | 152,100,000.00 | 5,544,493,000.00 | 236,500,000.00 | 0.00 | 1,739,049,000.00 | 88,869,000.00 | 1,650,180,000.00 | 425,100,000.00 | 425,005,000.00 | 3,210,410,000.00 | 755,614,000.00 | 18,784,000.00 | 49,536,000.00 | 2,386,476,000.00 | 35,538,706,000.00 | 20,258,376,000.00 | 33,700,000.00 | 58,928,000.00 | 0.00 | 65,102,000.00 | 274,044,000.00 | 0.00 | 136,203,000.00 | 137,841,000.00 | 0.00 | 13,797,402,000.00 | 13,222,810,000.00 | 574,592,000.00 | 5,788,849,000.00 | -6,434,920,000.00 | 12,223,769,000.00 | 468,719,000.00 | 837,649,000.00 | 7,533,323,000.00 | 3,313,317,000.00 | 70,761,000.00 | 0.00 | 15,280,330,000.00 | 27,000.00 | 6,154,000.00 | 0.00 | 18,784,000.00 | 2,210,856,000.00 | 4,304,843,000.00 | 458,435,000.00 | 1,817,357,000.00 | 360,945,000.00 | 1,668,106,000.00 | 289,654,000.00 | 0.00 | 5,757,974,000.00 | -45,765,000.00 | 5,803,739,000.00 | 2,692,038,000.00 | 1,922,694,000.00 | 769,344,000.00 | 269,118,000.00 | 500,226,000.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 154,755,168.00 | 154,755,168.00 | 4,713,039,000.00 | 5,724,462,000.00 | 11,006,120,000.00 | 30,285,905,000.00 | 9,735,837,000.00 | 11,006,120,000.00 | 242,079,000.00 | 24,803,522,000.00 | 28,635,725,000.00 | 24,803,522,000.00 | 0.00 | 24,803,522,000.00 | 1,216,210,000.00 | 21,250,814,000.00 | 712,098,000.00 | 154,755,000.00 | 154,755,000.00 | 10,735,184,000.00 | 5,190,691,000.00 | 25,000,000.00 | 152,114,000.00 | 24,927,000.00 | 1,028,237,000.00 | 3,985,413,000.00 | 153,210,000.00 | 3,832,203,000.00 | 152,100,000.00 | 5,544,493,000.00 | 236,500,000.00 | 0.00 | 1,739,049,000.00 | 88,869,000.00 | 1,650,180,000.00 | 425,100,000.00 | 425,005,000.00 | 3,210,410,000.00 | 755,614,000.00 | 18,784,000.00 | 49,536,000.00 | 2,386,476,000.00 | 35,538,706,000.00 | 20,258,376,000.00 | 33,700,000.00 | 58,928,000.00 | 0.00 | 65,102,000.00 | 274,044,000.00 | 0.00 | 136,203,000.00 | 137,841,000.00 | 0.00 | 13,797,402,000.00 | 13,222,810,000.00 | 574,592,000.00 | 5,788,849,000.00 | -6,434,920,000.00 | 12,223,769,000.00 | 468,719,000.00 | 837,649,000.00 | 7,533,323,000.00 | 3,313,317,000.00 | 70,761,000.00 | 0.00 | 15,280,330,000.00 | 27,000.00 | 6,154,000.00 | 0.00 | 18,784,000.00 | 2,210,856,000.00 | 4,304,843,000.00 | 458,435,000.00 | 1,817,357,000.00 | 360,945,000.00 | 1,668,106,000.00 | 289,654,000.00 | 0.00 | 5,757,974,000.00 | -45,765,000.00 | 5,803,739,000.00 | 2,692,038,000.00 | 1,922,694,000.00 | 769,344,000.00 | 269,118,000.00 | 500,226,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 154,564,194.00 | 154,564,194.00 | 0.00 | 545,588,000.00 | 14,052,694,000.00 | 21,604,380,000.00 | 8,911,394,000.00 | 14,052,694,000.00 | 282,438,000.00 | 21,341,230,000.00 | 21,341,230,000.00 | 21,386,129,000.00 | 44,899,000.00 | 21,341,230,000.00 | 626,535,000.00 | 18,427,069,000.00 | 522,758,000.00 | 154,564,000.00 | 154,564,000.00 | 4,687,893,000.00 | 850,737,000.00 | 31,664,000.00 | 0.00 | 31,664,000.00 | 475,591,000.00 | 206,176,000.00 | 206,176,000.00 | 0.00 | 137,306,000.00 | 3,837,156,000.00 | 88,201,000.00 | 0.00 | 339,412,000.00 | 76,262,000.00 | 263,150,000.00 | 455,180,000.00 | 455,180,000.00 | 2,818,022,000.00 | 492,442,000.00 | 19,838,000.00 | 60,945,000.00 | 2,244,797,000.00 | 26,074,022,000.00 | 13,325,472,000.00 | -90,321,000.00 | 56,885,000.00 | 0.00 | 64,310,000.00 | 128,074,000.00 | 0.00 | 853,000.00 | 127,221,000.00 | 0.00 | 7,288,536,000.00 | 6,713,944,000.00 | 574,592,000.00 | 5,780,226,000.00 | -5,829,203,000.00 | 11,609,429,000.00 | 251,124,000.00 | 814,265,000.00 | 7,280,874,000.00 | 3,192,405,000.00 | 70,761,000.00 | 0.00 | 12,748,550,000.00 | 1,843,592,000.00 | 42,612,000.00 | 0.00 | 19,838,000.00 | 1,821,875,000.00 | 4,099,611,000.00 | 507,637,000.00 | 1,879,571,000.00 | 188,726,000.00 | 1,523,677,000.00 | 424,309,000.00 | 216,934,000.00 | 5,556,868,000.00 | -38,721,000.00 | 5,595,589,000.00 | 566,503,000.00 | 1,062,000.00 | 565,441,000.00 | 18,200,000.00 | 547,241,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 154,564,194.00 | 154,564,194.00 | 39,591,000.00 | 449,879,000.00 | 17,201,604,000.00 | 18,423,694,000.00 | 12,073,287,000.00 | 17,201,604,000.00 | 123,433,000.00 | 18,097,248,000.00 | 18,097,248,000.00 | 18,134,299,000.00 | 37,051,000.00 | 18,097,248,000.00 | 17,942,684,000.00 | 15,847,935,000.00 | 522,758,000.00 | 154,564,000.00 | 154,564,000.00 | 4,246,853,000.00 | 794,116,000.00 | 49,322,000.00 | 125,714,000.00 | 49,322,000.00 | 567,666,000.00 | 51,414,000.00 | 51,414,000.00 | 0.00 | 125,714,000.00 | 3,452,737,000.00 | 99,404,000.00 | 79,019,000.00 | 398,465,000.00 | 72,019,000.00 | 326,446,000.00 | 279,796,000.00 | 279,796,000.00 | 2,605,859,000.00 | 637,295,000.00 | 20,311,000.00 | 79,019,000.00 | 1,869,234,000.00 | 22,381,152,000.00 | 6,855,128,000.00 | -73,212,000.00 | 52,731,000.00 | 0.00 | 69,430,000.00 | 130,940,000.00 | 0.00 | 1,853,000.00 | 129,087,000.00 | 0.00 | 895,644,000.00 | 321,052,000.00 | 574,592,000.00 | 5,700,893,000.00 | -5,381,233,000.00 | 11,082,126,000.00 | 260,011,000.00 | 794,580,000.00 | 7,005,879,000.00 | 2,880,045,000.00 | 141,611,000.00 | 0.00 | 15,526,024,000.00 | 928,228,000.00 | 46,662,000.00 | 0.00 | 21,662,000.00 | 691,009,000.00 | 3,474,468,000.00 | 291,286,000.00 | 1,652,451,000.00 | 241,377,000.00 | 1,289,354,000.00 | 295,051,000.00 | 170,378,000.00 | 3,890,191,000.00 | -50,707,000.00 | 3,940,898,000.00 | 6,936,603,000.00 | 6,649,748,000.00 | 286,855,000.00 | 33,856,000.00 | 252,999,000.00 |
| 2020-03-31T00:00:00 | annual | 5,909,090.00 | 0.00 | 0.00 | 4,857,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 73,868,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 60,205,000.00 | 0.00 | 0.00 | 0.00 | 71,138,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 565,698,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 156,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: JBCHEPHARM Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repurchase Of Capital Stock | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Payments | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net Intangibles Purchase And Sale | Sale Of Intangibles | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Stock Based Compensation | Provisionand Write Offof Assets | Depreciation And Amortization | Depreciation | Pension And Employee Benefit Expense | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 5,392,447,000.00 | 0.00 | -1,790,000,000.00 | 0.00 | 199,910,000.00 | -2,613,670,000.00 | 882,151,000.00 | 0.00 | 769,344,000.00 | -156,000.00 | 112,963,000.00 | -3,854,850,000.00 | 0.00 | -442,130,000.00 | -1,569,875,000.00 | -1,569,875,000.00 | 199,910,000.00 | 0.00 | 199,910,000.00 | -1,915,957,000.00 | -125,957,000.00 | 0.00 | -1,790,000,000.00 | -1,790,000,000.00 | 0.00 | -4,038,304,000.00 | 0.00 | 40,770,000.00 | 0.00 | -1,475,170,000.00 | 7,213,309,000.00 | -8,688,479,000.00 | 0.00 | 0.00 | -1,345,042,000.00 | 0.00 | -1,345,042,000.00 | -1,258,862,000.00 | 9,766,000.00 | -1,268,628,000.00 | 0.00 | 8,006,117,000.00 | -1,324,858,000.00 | -56,362,000.00 | 1,379,964,000.00 | -720,285,000.00 | -716,041,000.00 | 387,048,000.00 | 419,665,000.00 | 114,013,000.00 | 1,383,204,000.00 | 1,383,204,000.00 | 0.00 | -327,427,000.00 | -105,958,000.00 | 1,700,000.00 | 7,515,092,000.00 |
| 2023-03-31T00:00:00 | annual | -1,393,349,000.00 | 0.00 | -872,500,000.00 | 6,086,268,000.00 | 84,827,000.00 | -7,649,470,000.00 | 769,344,000.00 | 0.00 | 565,441,000.00 | 286,000.00 | 203,617,000.00 | 3,565,380,000.00 | -55,798,000.00 | -322,292,000.00 | -1,275,926,000.00 | -1,275,926,000.00 | 84,827,000.00 | 0.00 | 84,827,000.00 | 5,231,596,000.00 | 17,828,000.00 | 0.00 | 5,213,768,000.00 | -872,500,000.00 | 6,086,268,000.00 | -9,617,884,000.00 | 0.00 | 21,801,000.00 | 30,000.00 | -1,998,604,000.00 | 5,570,105,000.00 | -7,568,709,000.00 | 0.00 | 0.00 | -6,923,784,000.00 | 0.00 | -6,923,784,000.00 | -717,327,000.00 | 8,359,000.00 | -725,686,000.00 | 0.00 | 6,256,121,000.00 | -954,787,000.00 | -299,202,000.00 | 323,496,000.00 | -205,232,000.00 | -417,466,000.00 | 311,938,000.00 | 693,734,000.00 | 35,470,000.00 | 1,144,069,000.00 | 1,144,069,000.00 | 0.00 | -69,028,000.00 | -158,327,000.00 | -72,000.00 | 5,552,326,000.00 |
| 2022-03-31T00:00:00 | annual | -5,366,500,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7,067,900,000.00 | 565,400,000.00 | 0.00 | 224,700,000.00 | 0.00 | 340,700,000.00 | -1,383,900,000.00 | 0.00 | -24,600,000.00 | -1,275,600,000.00 | -1,275,600,000.00 | 0.00 | 0.00 | 0.00 | -3,300,000.00 | -3,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23,200,000.00 | 0.00 | 9,400,000.00 | 0.00 | 7,003,900,000.00 | 12,088,600,000.00 | -5,084,700,000.00 | 0.00 | 0.00 | -6,439,200,000.00 | 0.00 | -6,439,200,000.00 | -550,900,000.00 | 77,800,000.00 | -628,700,000.00 | 0.00 | 1,701,400,000.00 | -1,346,100,000.00 | -3,024,200,000.00 | 529,300,000.00 | -625,100,000.00 | -2,928,400,000.00 | 10,300,000.00 | 626,500,000.00 | 0.00 | 726,600,000.00 | 726,600,000.00 | 954,000.00 | -350,400,000.00 | 35,200,000.00 | -25,500,000.00 | 5,049,000,000.00 |
| 2021-03-31T00:00:00 | annual | 2,670,119,000.00 | 0.00 | 0.00 | 3,223,000.00 | 0.00 | -477,730,000.00 | 224,737,000.00 | -1,000.00 | 257,519,000.00 | 355,000.00 | -33,136,000.00 | -874,227,000.00 | 0.00 | -63,488,000.00 | -732,402,000.00 | -732,402,000.00 | 0.00 | 0.00 | 0.00 | 3,223,000.00 | 3,223,000.00 | 3,223,000.00 | 0.00 | 0.00 | 0.00 | -2,306,758,000.00 | -2,260,000.00 | 14,951,000.00 | 50,000.00 | -2,242,922,000.00 | 3,169,135,000.00 | -5,412,057,000.00 | -85,000,000.00 | -85,000,000.00 | 215,675,000.00 | 215,675,000.00 | 0.00 | -209,512,000.00 | 268,218,000.00 | -477,730,000.00 | 0.00 | 3,147,849,000.00 | -1,417,196,000.00 | -942,090,000.00 | 464,754,000.00 | -700,857,000.00 | -705,987,000.00 | 12,814,000.00 | 0.00 | 7,964,000.00 | 686,655,000.00 | 686,655,000.00 | -166,997,000.00 | -693,054,000.00 | 28,484,000.00 | -336,866,000.00 | 5,968,854,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | -1,608,190,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1,608,190,000.00 | 0.00 | 0.00 | 0.00 | 63,140,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5,398,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -729,677,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -67,674,000.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: JBCHEPHARM Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 8.70 | 0.00 | 900.62 | 32.87 | 32.87 | 552.63 | 138.32 | 1,202.95 | 933.48 | 795.16 | -39.90 | 43.65 | 4.43 | 528.46 | 552.63 | 2,695.04 | 2.02 | 15.86 | 15.50 | 0.00 | 0.00 | 552.63 | 552.63 | 0.00 | 552.63 | 0.00 | 552.63 | 552.63 | 198.88 | 751.51 | 0.10 | 0.12 | -0.12 | 0.00 | -39.90 | 0.68 | 43.65 | 4.43 | 752.64 | 1,492.09 | 329.47 | 138.32 | 138.32 | 415.51 | 381.81 | 33.70 | 2.02 | 2,244.72 | 1,202.95 | 3,447.67 | 3,447.67 |
| 2023-03-31T00:00:00 | annual | 1.98 | 0.00 | 697.47 | 7.57 | 7.57 | 409.84 | 114.41 | 1,184.80 | 705.05 | 590.64 | -33.52 | 35.41 | 2.54 | 404.24 | 409.84 | 2,529.02 | 2.95 | 7.83 | 7.73 | 0.00 | 0.00 | 409.84 | 409.84 | 0.00 | 409.84 | -0.17 | 410.01 | 410.01 | 145.23 | 555.23 | 0.37 | 0.67 | -0.67 | 0.00 | -33.52 | 0.64 | 35.41 | 2.54 | 587.49 | 1,344.22 | 303.88 | 114.41 | 114.41 | 375.29 | 338.50 | 36.79 | 2.95 | 1,931.71 | 1,184.80 | 3,116.51 | 3,116.51 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 582.68 | 37.45 | 37.45 | 385.36 | 72.66 | 842.94 | 582.68 | 510.02 | -5.12 | 5.12 | 0.93 | 385.36 | 385.36 | 1,953.45 | 1.34 | 15.47 | 15.46 | 0.00 | 0.00 | 385.36 | 385.36 | 0.00 | 385.36 | -0.68 | 386.04 | 386.04 | 118.86 | 504.90 | 39.23 | 2.40 | -2.40 | 0.00 | -5.12 | 0.34 | 5.12 | 0.93 | 470.79 | 1,110.51 | 598.61 | 72.66 | 72.66 | 316.10 | 258.11 | 57.99 | 1.34 | 1,581.30 | 842.94 | 2,424.24 | 2,424.24 |
| 2021-03-31T00:00:00 | annual | 25.58 | 0.00 | 569.58 | 102.91 | 102.91 | 447.96 | 68.67 | 717.44 | 672.49 | 603.83 | -5.47 | 6.94 | 1.77 | 370.63 | 447.96 | 1,531.32 | 1.15 | 15.46 | 15.46 | 0.00 | 0.00 | 447.96 | 447.96 | 0.00 | 447.96 | -0.56 | 448.52 | 448.52 | 148.36 | 596.89 | 7.62 | 52.36 | -52.44 | 0.08 | -5.47 | 0.30 | 6.94 | 1.77 | 487.59 | 813.89 | 203.57 | 68.67 | 68.67 | 198.05 | 177.09 | 20.96 | 1.15 | 1,301.48 | 717.44 | 2,018.91 | 2,018.91 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
38.41
P/E
47.706326
P/B
8.859664
Dividend Yield
0.71%
Market Cap
28,547.88 Cr.
Face Value
206.825
Book Value
206.825
ROE
16.47%
EBITDA Growth
964.87 Cr.
Debt/Equity
3.12
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of jbchepharm?
The market capitalization of J. B. Chemicals & Pharmaceuticals Limited is ₹28,548 Cr as of 05 Feb 2025.
What are the PE and PB ratios of J. B. Chemicals & Pharmaceuticals Limited?
The PE and PB ratios of J. B. Chemicals & Pharmaceuticals Limited are Not Available and 8.859664 respectively as of 05 Feb 2025.
What is the 52 Week High of J. B. Chemicals & Pharmaceuticals Limited?
The 52-week high of J. B. Chemicals & Pharmaceuticals Limited is ₹2030 as of 05 Feb 2025.
What is the 52 Week Low of J. B. Chemicals & Pharmaceuticals Limited?
The 52-week low of J. B. Chemicals & Pharmaceuticals Limited is ₹1480 as of 05 Feb 2025.
What are the earnings per share (EPS) for J. B. Chemicals & Pharmaceuticals Limited?
The Earnings Per Share (EPS) of J. B. Chemicals & Pharmaceuticals Limited is ₹38.41 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of J. B. Chemicals & Pharmaceuticals Limited?
The Return on Equity (ROE) of J. B. Chemicals & Pharmaceuticals Limited is 16.47% as per the most recent financial year data. Explore more on Fincept.